Literature DB >> 22160757

Prediction of drug response and safety in clinical practice.

Andrew A Monte1, Kennon J Heard, Vasilis Vasiliou.   

Abstract

Many clinicians hoped that the completion of the Human Genome Project would result in "individualized drug therapy," i.e., determining the right medication at the right dose 100% of the time based upon the individual's genetics. The pharmacogenomic prediction of drug efficacy and safety has not become a reality due to continuing realization of the complexity dictating the human-drug interaction. New methods of metabolomics, proteomics, and transcriptomics that account for this complexity hold promise for translational researchers hoping to increase drug efficacy and decrease drug toxicity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22160757      PMCID: PMC3550218          DOI: 10.1007/s13181-011-0198-7

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  58 in total

1.  Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype.

Authors:  A Gaedigk; J D Eklund; R E Pearce; J S Leeder; S W Alander; M S Phillips; L D Bradford; M J Kennedy
Journal:  Clin Pharmacol Ther       Date:  2007-03-28       Impact factor: 6.875

Review 2.  Structure of cytochrome p450s and personalized drug.

Authors:  Jing-Fang Wang; Cheng-Cheng Zhang; Kuo-Chen Chou; Dong-Qing Wei
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

3.  A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.

Authors:  Bruno Georg Oertel; Mattias Kettner; Klaus Scholich; Christoph Renné; Bianca Roskam; Gerd Geisslinger; Peter Harald Schmidt; Jörn Lötsch
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

Review 4.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 5.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Authors:  Daniel W Nebert; Ge Zhang; Elliot S Vesell
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 6.  Drug interactions with smoking.

Authors:  Lisa A Kroon
Journal:  Am J Health Syst Pharm       Date:  2007-09-15       Impact factor: 2.637

Review 7.  Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.

Authors:  Ichiro Ieiri; Shun Higuchi; Yuichi Sugiyama
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-07       Impact factor: 4.481

8.  The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.

Authors:  M C Rebsamen; J Desmeules; Y Daali; A Chiappe; A Diemand; C Rey; J Chabert; P Dayer; D Hochstrasser; M F Rossier
Journal:  Pharmacogenomics J       Date:  2008-07-01       Impact factor: 3.550

9.  Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.

Authors:  P Madadi; C J D Ross; M R Hayden; B C Carleton; A Gaedigk; J S Leeder; G Koren
Journal:  Clin Pharmacol Ther       Date:  2008-08-20       Impact factor: 6.875

10.  Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.

Authors:  Chi Chen; Kristopher W Krausz; Yatrik M Shah; Jeffrey R Idle; Frank J Gonzalez
Journal:  Chem Res Toxicol       Date:  2009-04       Impact factor: 3.739

View more
  7 in total

1.  The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.

Authors:  Andrew A Monte; Kennon J Heard; Jenny Campbell; D Hamamura; Richard M Weinshilboum; Vasilis Vasiliou
Journal:  Acad Emerg Med       Date:  2014-08-24       Impact factor: 3.451

2.  CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction.

Authors:  Andrew A Monte; Kelsey West; Kyle T McDaniel; Hania K Flaten; Jessica Saben; Shelby Shelton; Farah Abdelmawla; Lane R Bushman; Kayla Williamson; Diana Abbott; Peter L Anderson
Journal:  Clin Pharmacol Ther       Date:  2018-07-25       Impact factor: 6.875

3.  Metabolic changes in rats after intragastric administration of MGCD0103 (Mocetinostat), a HDAC class I inhibitor.

Authors:  Qingwei Zhang; Haiya Wu; Congcong Wen; Fa Sun; Xuezhi Yang; Lufeng Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  CYP2C19 drug-drug and drug-gene interactions in ED patients.

Authors:  Hanna K Flaten; Howard S Kim; Jenny Campbell; Lisa Hamilton; Andrew A Monte
Journal:  Am J Emerg Med       Date:  2015-11-09       Impact factor: 2.469

5.  Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice.

Authors:  Andrew A Monte; Vasilis Vasiliou; Kennon J Heard
Journal:  J Pharmacogenomics Pharmacoproteomics       Date:  2012-03-16

Review 6.  Improved drug therapy: triangulating phenomics with genomics and metabolomics.

Authors:  Andrew A Monte; Chad Brocker; Daniel W Nebert; Frank J Gonzalez; David C Thompson; Vasilis Vasiliou
Journal:  Hum Genomics       Date:  2014-09-01       Impact factor: 4.639

Review 7.  Pharmacogenomics in oncology care.

Authors:  Kelly K Filipski; Leah E Mechanic; Rochelle Long; Andrew N Freedman
Journal:  Front Genet       Date:  2014-04-08       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.